List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3434143/publications.pdf Version: 2024-02-01



PONC WANC

#	Article	IF	CITATIONS
1	Proximity to endocrine-disrupting pesticides and risk of testicular germ cell tumors (TGCT) among adolescents: A population-based case-control study in California. International Journal of Hygiene and Environmental Health, 2022, 239, 113881.	2.1	7
2	The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leukemia and Lymphoma, 2022, 63, 1651-1659.	0.6	5
3	Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances, 2022, 6, 3339-3342.	2.5	5
4	OUP accepted manuscript. Oncologist, 2022, , .	1.9	1
5	Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia. JCO Oncology Practice, 2022, 18, e1060-e1068.	1.4	7
6	Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL. Blood Advances, 2022, 6, 3756-3766.	2.5	3
7	Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses Journal of Clinical Oncology, 2022, 40, 7554-7554.	0.8	Ο
8	Socioeconomic status and childhood central nervous system tumors in California. Cancer Causes and Control, 2021, 32, 27-39.	0.8	13
9	Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia, 2021, 35, 1643-1660.	3.3	29
10	Birth Characteristics and Risk of Pediatric Thyroid Cancer: A Population-Based Record-Linkage Study in California. Thyroid, 2021, 31, 596-606.	2.4	8
11	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia and Lymphoma, 2021, 62, 1-10.	0.6	0
12	Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 177-189.	0.9	14
13	Sociodemographic and hospitalâ€based predictors of intense endâ€ofâ€life care among children, adolescents, and young adults with hematologic malignancies. Cancer, 2021, 127, 3817-3824.	2.0	7
14	Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e551-e558.	0.2	3
15	Cytokine Levels at Birth in Children Who Developed Acute Lymphoblastic Leukemia. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1526-1535.	1.1	5
16	Outdoor artificial light at night, air pollution, and childhood acute lymphoblastic leukemia. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
17	Mode of Delivery, Birth Characteristics, and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case–Control Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2286-2293.	1.1	3
18	Physical Therapy Utilization Among Hospitalized Patients with Pediatric Acute Lymphoblastic Leukemia. Blood, 2021, 138, 4024-4024.	0.6	0

#	Article	IF	CITATIONS
19	Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. Blood, 2021, 138, 4092-4092.	0.6	0
20	Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis. Blood, 2021, 138, 182-182.	0.6	0
21	Lifestyle factors and risk of myeloproliferative neoplasms in the NIHâ€AARP diet and health study. International Journal of Cancer, 2020, 147, 948-957.	2.3	9
22	Spatial–Temporal Cluster Analysis of Childhood Cancer in California. Epidemiology, 2020, 31, 214-223.	1.2	7
23	Comprehensive Analysis of the Glycome and Glycoproteome of Bovine Milk-Derived Exosomes. Journal of Agricultural and Food Chemistry, 2020, 68, 12692-12701.	2.4	29
24	Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2343-2350.	1.1	1
25	Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e712-e723.	0.2	12
26	Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances, 2020, 4, 2192-2201.	2.5	68
27	Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption. International Journal of Cancer, 2020, 146, 3523-3523.	2.3	1
28	Age-, sex- and disease subtype–related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. European Journal of Cancer, 2020, 130, 1-11.	1.3	7
29	Development of 3-mercaptopropyltrimethoxysilane (MPTS)-modified bone marrow mononuclear cell membrane chromatography for screening anti-osteoporosis components from Scutellariae Radix. Acta Pharmaceutica Sinica B, 2020, 10, 1856-1865.	5.7	27
30	Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica, 2020, 105, 2659-2663.	1.7	66
31	Birth Characteristics and Risk of Early-Onset Synovial Sarcoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1162-1167.	1.1	3
32	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews, 2020, 42, 100706.	2.8	54
33	Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood, 2020, 136, 13-14.	0.6	10
34	Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status Journal of Clinical Oncology, 2020, 38, e19057-e19057.	0.8	0
35	Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study. Blood, 2020, 136, 2-3.	0.6	0
36	Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes. Blood, 2020, 136, 2-3.	0.6	1

#	Article	IF	CITATIONS
37	Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia. Blood, 2020, 136, 21-22.	0.6	1
38	Patterns of Care and Outcomes Among Older Patients with Myelofibrosis: A Population-Based Study. Blood, 2020, 136, 21-22.	0.6	1
39	Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood, 2020, 136, 44-45.	0.6	0
40	Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology, 2019, 124, 98-106.	0.5	9
41	Underutilization of guidelineâ€recommended supportive care among older adults with multiple myeloma in the United States. Cancer, 2019, 125, 4084-4095.	2.0	10
42	Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectrum, 2019, 3, pkz030.	1.4	0
43	Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A populationâ€ŀevel analysis. Cancer, 2019, 125, 4241-4251.	2.0	28
44	Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release. Journal of Nanomaterials, 2019, 2019, 1-13.	1.5	10
45	Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology. Haematologica, 2019, 104, e514-e516.	1.7	8
46	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews, 2019, 36, 70-87.	2.8	484
47	AUTHOR REPLY. Urology, 2019, 124, 106.	0.5	0
48	Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. Cancer Epidemiology, 2019, 59, 158-165.	0.8	23
49	Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews, 2019, 34, 1-15.	2.8	117
50	Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States. Blood, 2019, 134, 646-646.	0.6	7
51	Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). Blood, 2019, 134, 4748-4748.	0.6	1
52	Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents Journal of Clinical Oncology, 2019, 37, 8044-8044.	0.8	3
53	Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 211-219.	2.3	6
54	GWAS in childhood acute lymphoblastic leukemia reveals novel genetic associations at chromosomes 17q12 and 8q24.21. Nature Communications, 2018, 9, 286.	5.8	75

#	Article	IF	CITATIONS
55	Porcine reproductive and respiratory syndrome virus induces HMGB1 secretion via activating PKC-delta to trigger inflammatory response. Virology, 2018, 518, 172-183.	1.1	18
56	Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer, 2018, 124, 4211-4220.	2.0	9
57	Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. European Journal of Epidemiology, 2018, 33, 965-976.	2.5	44
58	<i>BMI1</i> enhancer polymorphism underlies chromosome 10p12.31 association with childhood acute lymphoblastic leukemia. International Journal of Cancer, 2018, 143, 2647-2658.	2.3	23
59	Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nature Medicine, 2018, 24, 39-49.	15.2	236
60	Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. Blood, 2018, 132, 3538-3538.	0.6	0
61	Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States. Blood, 2018, 132, 978-978.	0.6	0
62	Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. Blood, 2018, 132, 3580-3580.	0.6	2
63	Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the <scp>U</scp> nited <scp>S</scp> tates: A large populationâ€based study. Cancer, 2017, 123, 3754-3762.	2.0	18
64	Cesarean Section and Risk of Childhood Acute Lymphoblastic Leukemia in a Population-Based, Record-Linkage Study in California. American Journal of Epidemiology, 2017, 185, 96-105.	1.6	34
65	SH2 Domain–Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 500-514.	2.5	49
66	Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Populationâ€Based Study. Prostate, 2017, 77, 437-445.	1.2	24
67	Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leukemia and Lymphoma, 2017, 58, 982-985.	0.6	16
68	Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. Journal of Clinical Oncology, 2017, 35, 3417-3424.	0.8	61
69	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLoS ONE, 2017, 12, e0184747.	1.1	9
70	Physician volume and discontinuation of rituximab during lymphoma treatment Journal of Clinical Oncology, 2017, 35, 6593-6593.	0.8	0
71	Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study Journal of Clinical Oncology, 2017, 35, 7057-7057.	0.8	0
72	Diseaseâ€related costs of care and survival among <scp>M</scp> edicareâ€enrolled patients with myelodysplastic syndromes. Cancer, 2016, 122, 1598-1607.	2.0	19

#	Article	IF	CITATIONS
73	Birth weight and risk of paediatric Hodgkin lymphoma: Findings from a population-based record linkage study in California. European Journal of Cancer, 2016, 69, 19-27.	1.3	11
74	The antinociception of oxytocin on colonic hypersensitivity in rats was mediated by inhibition of mast cell degranulation via Ca2+-NOS pathway. Scientific Reports, 2016, 6, 31452.	1.6	20
75	The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. Health Services Research, 2016, 51, 167-186.	1.0	16
76	Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood, 2016, 128, 1188-1188.	0.6	1
77	The impact of androgen deprivation and pelvic radiation on the development of bladder cancer Journal of Clinical Oncology, 2016, 34, 439-439.	0.8	2
78	Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood, 2016, 128, 394-394.	0.6	0
79	Disease Risk Estimation by Combining Case–Control Data with Aggregated Information on the Population at Risk. Biometrics, 2015, 71, 114-121.	0.8	3
80	Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. Blood, 2015, 126, 1676-1676.	0.6	0
81	Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood, 2015, 126, 3285-3285.	0.6	1
82	Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). Blood, 2015, 126, 873-873.	0.6	5
83	Antagonizing Interferon-Mediated Immune Response by Porcine Reproductive and Respiratory Syndrome Virus. BioMed Research International, 2014, 2014, 1-9.	0.9	51
84	Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care. Medical Care, 2014, 52, 680-687.	1.1	18
85	Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal of the National Cancer Institute, 2014, 106, .	3.0	22
86	The cost implications of prostate cancer screening in the Medicare population. Cancer, 2014, 120, 96-102.	2.0	50
87	A New Estimation Approach for Combining Epidemiological Data From Multiple Sources. Journal of the American Statistical Association, 2014, 109, 11-23.	1.8	3
88	The cost implications of prostate cancer screening in the Medicare population Journal of Clinical Oncology, 2013, 31, 6549-6549.	0.8	0
89	Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries. Archives of Internal Medicine, 2012, 172, 1601.	4.3	26
90	Patterns of subsequent malignancies after <scp>H</scp> odgkin lymphoma in children and adults. British Journal of Haematology, 2012, 158, 615-625.	1.2	28

Article	IF	CITATIONS
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leukemia Research, 2012, 36, 1370-1375.	0.4	25
The evolution of breast cancer screening in the Medicare population: Clinical and economic implications Journal of Clinical Oncology, 2012, 30, 1595-1595.	0.8	0
Regional variation in treatment costs and survival for elderly patients with myelodysplastic syndromes Journal of Clinical Oncology, 2012, 30, 6628-6628.	0.8	0
Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes and Control, 2011, 22, 623-629.	0.8	10
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leukemia Research, 2011, 35, 904-908.	0.4	16
Ascertainment of Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2011, 29, e16-e16.	0.8	8
Clarification on the categorization of comorbidities. Leukemia Research, 2010, 34, e74.	0.4	3
Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH-AARP Cohort. American Journal of Epidemiology, 2010, 171, 312-322.	1.6	54
A Birth Cohort Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 1973–2004. Thyroid, 2009, 19, 1061-1066.	2.4	120
Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort. American Journal of Epidemiology, 2009, 169, 1492-1499.	1.6	68
Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States. Cancer Causes and Control, 2009, 20, 1369-1376.	0.8	12
Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leukemia Research, 2009, 33, 1594-1598.	0.4	83
Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut Women. American Journal of Epidemiology, 2008, 169, 176-185.	1.6	58
Personal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin Lymphoma. American Journal of Epidemiology, 2008, 167, 1321-1331.	1.6	98
Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma. American Journal of Epidemiology, 2007, 165, 1255-1264.	1.6	37
Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2007, 18, 351-359.	0.8	6
Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birth Place, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	0
	ARTICLE   The Impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leukemia Research, 2012, 45, 1370-1375.   The evolution of breast cancer screening in the Medicare population: Clinical and economic implications. Journal of Clinical Oncology, 2012, 30, 1595-1595.   Regional variation in treatment costs and survival for elderly patients with myelodysplastic syndromes. Cancer Causes and Control, 2011, 22, 623-629.   Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes and Control, 2011, 22, 623-629.   Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Cancer Causes and Control, 2011, 23, 623-629.   Clarification on the categorization of comorbidities. Leukemia Research, 2010, 34, e74.   Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH-AARP Cohort. American Journal of Epidemiology, 2009, 169, 1492-1499.   Alighth Cohort. Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 1973&C'2004. Thyrold, 2009, 169, 1492-1499.   Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes. Concer Causes and Control, 2009, 20, 159, 1376.   Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leukemia Research, 2009, 31, 159-1595.   Personal Use of Hair Dye and the Risk of Certain Subhypes of Non-Hodgkin Lymphoma. American Journal of Epidemiology, 2008, 169, 176-185.   Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma	Attrict IF   The impact of hypomethylating agents on the cost of carse and survival of elderly patients with myelodysplastic syndromes. Leukemia Research, 2012, 36, 1370-1375. 0.4   The evolution of breast cancer screening in the Medicare population: Clinical and economic implications. Journal of Clinical Oncology, 2012, 30, 1595-1595. 0.4   Regional variation in treatment costs and survival for elderly patients with myelodysplastic syndromes. Journal of Clinical Oncology, 2012, 30, 6528-6528. 0.4   Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes and Control, 2011, 22, 623-629. 0.4   Pattern of Hypomethylating agents use among elderly patients with myelodysplastic syndromes. Cancer Causes and Control, 2011, 25, 504-908. 0.4   Clarification on the categorization of comorbidities. Leukemia Research, 2010, 34, e74. 0.4   Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH-AARP Cohort. American Journal of Epidemiology. 1.0   ABirth Cohort Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 19736C2004. 2.4   Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort. American Journal of Epidemiology. 0.6   Consolidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. 0.4   Pattern Leukemia Research, 2009, 33, 1594-1598. 0.4   Diet, Lifestyle, Factors, and Risk of Myelodysplastic